Evidence map›Paper›PMID 42697881›Full record

ArticleNature communications2026

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.

Diego Gilioli, Simona Fusco, Teresa Tavella, Tatiana Volpari, Antonella Santoro, Martin Schönlein, Kety Giannetti, Edoardo Carsana, Nicolò Gualandi, Roberta Noberini and 27 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Diego Gilioli *San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Simona Fusco *San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-8272-7902
Teresa TavellaSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-2298-4413
Tatiana VolpariSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Antonella SantoroSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-1012-888X
Martin SchönleinResearch Institute of Molecular Pathology (IMP), Wien, Austria.ORCID http://orcid.org/0000-0002-1010-0975
Kety GiannettiSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Edoardo CarsanaSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0009-0008-6200-2868
Nicolò GualandiSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0003-0622-6118
Roberta NoberiniDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Chiara BrombinUniversity Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy.
Salvatore RussoDrug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Sara FeolaDrug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-4012-4310
Yvonne GiannoulaDrug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4265-5411
Rui M M BrancaScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
Janne LehtiöScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden.
Tiina M SikanenDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki; Viikinkaari 5E, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0788-1301
Markus HaapalaDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki; Viikinkaari 5E, Helsinki, Finland.ORCID http://orcid.org/0000-0001-7828-8663
Laura PasseriniSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Angela AndrisaniUnit of Immunogenetics, Leukaemia Genomics and Immunobiology, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giacomo FarinaSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Alessia ZangariSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Anastasia ContiSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-8670-2649
Lucrezia Della VolpeSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-9087-1293
Matteo BarcellaSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Stefano BerettaSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Federico Mario AlettiHematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Matteo Giovanni CarrabbaHematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0001-7015-4839
Silvia GregoriSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0002-3517-9683
Chiara BoniniVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0002-0772-1674
Ivan MerelliSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0003-3587-3680
Fabio CiceriVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0003-0873-0123
Vincenzo CerulloDrug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4901-3796
Tiziana BonaldiDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0003-3556-1265
Luca VagoVita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0003-4247-3175
Clemens A SchmittMedical Department of Hematology, Oncology and Tumor Immunology, Charité- Universitätsmedizin, Berlin, Germany.ORCID http://orcid.org/0000-0002-4731-2226
Raffaella Di MiccoSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy. dimicco.raffaella@hsr.it.ORCID http://orcid.org/0000-0002-0639-8238

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) MFAG 2019 Id23321 plus Bridge grantEuropean Commission (EC) ERC Consolidator grant 101003186 ReviveSTEMEuropean Hematology Association (EHA) Advanced research grant 2019Leukemia Research Foundation (LRF) Hollis Brownstein Research Grant
6 · The paper itself

Abstract

Chemotherapy resistance and disease relapse are major determinants of treatment failure in acute myeloid leukemia (AML). Therapy-induced senescence (TIS) is one outcome of chemotherapy, but its immunological consequences in AML remain unclear. Here we show that ex vivo chemotherapy induces senescence in a subset of therapy-naïve AML samples. TIS is marked by elevated interferon signaling, upregulation of human leukocyte antigen (HLA) class I and II molecules, and increased presentation of leukemia- and senescence-associated peptides, conferring AML cells antigen-presenting cell-like features. These changes enhance autologous CD4

Indexed as

Cellular SenescenceEnhancer of Zeste Homolog 2 ProteinLeukemia, Myeloid, AcuteAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansLymphocyte ActivationMicePolycomb Repressive Complex 2Xenograft Model Antitumor AssaysEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPolycomb Repressive Complex 2

Identifiers

PMID42697881
PMCPMC13545235

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.